These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 18028023)

  • 1. Mechanisms of mammalian target of rapamycin inhibition in sarcoma: present and future.
    MacKenzie AR; von Mehren M
    Expert Rev Anticancer Ther; 2007 Aug; 7(8):1145-54. PubMed ID: 18028023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The biology behind mTOR inhibition in sarcoma.
    Wan X; Helman LJ
    Oncologist; 2007 Aug; 12(8):1007-18. PubMed ID: 17766661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The potential role of mTOR inhibitors in non-small cell lung cancer.
    Gridelli C; Maione P; Rossi A
    Oncologist; 2008 Feb; 13(2):139-47. PubMed ID: 18305058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mammalian target of rapamycin is a promising target for novel therapeutic strategy against cancer.
    Bjelogrlić SK; Srdić T; Radulović S
    J BUON; 2006; 11(3):267-76. PubMed ID: 17309148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic targets: MTOR and related pathways.
    Dancey JE
    Cancer Biol Ther; 2006 Sep; 5(9):1065-73. PubMed ID: 16969122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Everolimus (RAD001) and solid tumours: a 2008 summary].
    Lévy A; Sauvin LA; Massard C; Soria JC
    Bull Cancer; 2008 Dec; 95(12):1205-11. PubMed ID: 19091655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The mammalian target of the rapamycin (mTOR) kinase pathway: its role in tumourigenesis and targeted antitumour therapy.
    Janus A; Robak T; Smolewski P
    Cell Mol Biol Lett; 2005; 10(3):479-98. PubMed ID: 16217558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies.
    Yee KW; Zeng Z; Konopleva M; Verstovsek S; Ravandi F; Ferrajoli A; Thomas D; Wierda W; Apostolidou E; Albitar M; O'Brien S; Andreeff M; Giles FJ
    Clin Cancer Res; 2006 Sep; 12(17):5165-73. PubMed ID: 16951235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mammalian target of rapamycin inhibitors in sarcomas.
    Okuno S
    Curr Opin Oncol; 2006 Jul; 18(4):360-2. PubMed ID: 16721131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring antitumor efficacy of rapamycin in Kaposi sarcoma.
    Di Paolo S; Teutonico A; Ranieri E; Gesualdo L; Schena PF
    Am J Kidney Dis; 2007 Mar; 49(3):462-70. PubMed ID: 17336708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro.
    Gorshtein A; Rubinfeld H; Kendler E; Theodoropoulou M; Cerovac V; Stalla GK; Cohen ZR; Hadani M; Shimon I
    Endocr Relat Cancer; 2009 Sep; 16(3):1017-27. PubMed ID: 19509067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [mTOR signal pathway and its inhibitors in antitumor therapy: a review].
    Huang JJ; Lin TY
    Ai Zheng; 2007 Dec; 26(12):1397-403. PubMed ID: 18076811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapamycin selectively inhibits expression of an inducible keratin (K6a) in human keratinocytes and improves symptoms in pachyonychia congenita patients.
    Hickerson RP; Leake D; Pho LN; Leachman SA; Kaspar RL
    J Dermatol Sci; 2009 Nov; 56(2):82-8. PubMed ID: 19699613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. mTOR inhibitors in hematologic malignancies.
    Dancey JE
    Clin Adv Hematol Oncol; 2003 Jul; 1(7):419-23. PubMed ID: 16258427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of mTOR radiosensitizes soft tissue sarcoma and tumor vasculature.
    Murphy JD; Spalding AC; Somnay YR; Markwart S; Ray ME; Hamstra DA
    Clin Cancer Res; 2009 Jan; 15(2):589-96. PubMed ID: 19147764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mammalian target of rapamycin (mTOR) pathway signalling in lymphomas.
    Drakos E; Rassidakis GZ; Medeiros LJ
    Expert Rev Mol Med; 2008 Feb; 10():e4. PubMed ID: 18241520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Mammalian target of rapamycin, its mode of action and clinical response in metastatic clear cell carcinoma].
    Shuuin T; Karashima H
    Gan To Kagaku Ryoho; 2009 Jul; 36(7):1076-9. PubMed ID: 19620795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mammalian target of rapamycin inhibitors in renal cell carcinoma: current status and future applications.
    Pantuck AJ; Thomas G; Belldegrun AS; Figlin RA
    Semin Oncol; 2006 Oct; 33(5):607-13. PubMed ID: 17045090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting mTOR for cancer treatment.
    Rubio-Viqueira B; Hidalgo M
    Curr Opin Investig Drugs; 2006 Jun; 7(6):501-12. PubMed ID: 16784020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis.
    Shor B; Zhang WG; Toral-Barza L; Lucas J; Abraham RT; Gibbons JJ; Yu K
    Cancer Res; 2008 Apr; 68(8):2934-43. PubMed ID: 18413763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.